CG Oncology Conference: Credo Posts 75.5% CR in BOND-003, BLA Filing Targeted for 2026 [Yahoo! Finance]
CG Oncology, Inc. - Common stock (CGON)
Company Research
Source: Yahoo! Finance
CG Oncology logo Key Points BOND-003 Cohort C showed a 75.5% complete response rate "at any time" in 110 BCG-unresponsive CIS patients, a 12-month CR of 46.4%, and roughly 90% of 12-month responders remained in CR at 24 months with no drug-related grade 3 adverse events reported. Regulatory and commercial timeline : CG Oncology expects to complete a BLA for the BCG-unresponsive high-risk indication in (CMC/process validation are the main outstanding items) and is targeting an intermediate-risk filing from PIVOT-006 in , while building a ~ 75–80 person launch organization. Broader program and combos : the company is advancing multiple cohorts—including an 88% CR signal in a BCG-naive optimized cohort—and is studying Credo with gemcitabine with early data expected in H1, positioning the intravesical therapy to fit existing urology workflows similar to BCG. Interested in CG Oncology, Inc.? Here are five stocks we like better. Discover the 3 Best-Performing Biotech IPO Stocks
Show less
Read more
Impact Snapshot
Event Time:
CGON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGON alerts
High impacting CG Oncology, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CGON
News
- CG Oncology (CGON) had its price target raised by JPMorgan Chase & Co. from $65.00 to $91.00. They now have an "overweight" rating on the stock.MarketBeat
- CG Oncology (CGON) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CGON&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "hoMarketBeat
- CG Oncology (CGON) had its price target raised by HC Wainwright from $80.00 to $100.00. They now have a "buy" rating on the stock.MarketBeat
- CG Oncology: Passing A Red Line For What I Would Call A Reasonable Valuation (Rating Downgrade) [Seeking Alpha]Seeking Alpha
- CG Oncology (CGON) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=CGON&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "MarketBeat
CGON
Earnings
- 11/14/25 - In-Line
CGON
Sec Filings
- 4/17/26 - Form 144
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- CGON's page on the SEC website